

DAFTAR PUSTAKA

- Ali, E.M., Ahmed, A.R.H., Ali, A.M.A., 2014. Correlation of Breast Cancer Subtypes Based on ER, PR and HER2 Expression with Axillary Lymph Node Status. *Cancer Oncol. Res.* 2, 51–57.
- Ambroise, M., Ghosh, M., Mallikarjuna, V., Kurian, A., 2011. Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in South India. *Asian Pacific J Cancer Prev* 12, 625–629.
- Anderson, W.F., Pfeiffer, R.M., Dores, G.M., Sherman, M.E., 2006. Comparison of age distribution patterns for different histopathologic types of breast carcinoma. *Cancer Epidemiol. Biomarkers Prev.* 15, 1899–1905.
- Asselin-Labat, M.L., Sutherland, K.D., Barker, H., Thomas, R., Shackleton, M., Forrest, N.C., Hartley, L., Robb, L., Grosveld, F.G., van der Wees, J., Lindeman, G.J., Visvader, J.E., 2007. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. *Nat Cell Biol* 9, 201–209.
- Ayadi, L., Khabir, A., Amouri, H., Karray, S., Dammak, A., Guermazi, M., Boudawara, T., 2008. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma. *World J. Surg. Oncol.* 6, 112.
- Azizun-Nisa, Bhurgri, Y., Raza, F., Kayani, N., 2008. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. *Asian Pacific J. Cancer Prev.* 9, 553–556.
- Bauer, K.R., Brown, M., Cress, R.D., Parise, C.A., Caggiano, V., 2007. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California Cancer Registry. *Cancer* 109, 1721–1728.
- Behrooz, A., 1997. Dual Control of glut1 Glucose Transporter Gene Expression by Hypoxia and by Inhibition of Oxidative Phosphorylation *. *J. Biol. Chem.* 272, 5555–5562.
- Bhatia, J.K., Metzger, D., Ashamalla, H., Katsoulakis, E., Mattes, M.D., 2014. Breast Cancer Molecular Subtype as a Predictor of Lymph Node Metastasis. *Int. J. Radiat. Oncol.* 90, S267–S268.
- Bloom, H., Richardson, W., 1957. Histological Grading and Prognosis in Breast Cancer A Study of 1409 Cases of Which 359 Have Been Followed for 15 Years. *Br. J. Cancer* 11, 359–377.
- Burstein, H.J., Storniolo, A.M., Franco, S., Forster, J., Stein, S., Rubin, S.,

- Salazar, V.M., Blackwell, K.L., 2008. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. *Ann. Oncol.* 19, 1068–1074.
- Cheang, M.C.U., Chia, S.K., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, M., Davies, S., Bernard, P.S., Parker, J.S., Perou, C.M., Ellis, M.J., Nielsen, T.O., 2009. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. *J. Natl. Cancer Inst.* 101, 736–750.
- Chen, W., Lai, Y., Chen, H., Guo, H., Su, I., Chen, H.H.W., W-c, C., Y-h, L., H-y, C., H-r, G., I-j, S., Chen, H.H.W., 2013. Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor. *Histopathology* 17, 225–233.
- Chen, X.S., Ma, C.D., Wu, J.Y., Yang, W.T., Lu, H.F., Wu, J., Lu, J.S., Shao, Z.M., Shen, Z.Z., Shen, K.W., 2010. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer. *Tumori* 96, 103–110.
- Cheng, H., Qin, Y., Fan, H., Su, P., Zhang, X., Zhang, H., Zhou, G., 2013. Overexpression of CARM1 in breast cancer is correlated with poorly characterized clinicopathologic parameters and molecular subtypes. *Diagn. Pathol.* 8, 1.
- Choi, J., Jung, W., Koo, J., 2013. Metabolism-Related Proteins Are Differentially Expressed according to the Molecular Subtype of Invasive Breast Cancer Defined by Surrogate Immunohistochemistry. *Pathobiology* 80, 41–52.
- Creighton, C.J., 2012. The molecular profile of luminal B breast cancer. *Biol. Targets Ther.* 6, 289–297.
- Da Silva, L., Lakhani, S.R., 2010. Pathology of hereditary breast cancer. *Mod. Pathol.* 23, 46–51.
- Dammann, R., Yang, G., Pfeifer, G.P., 2001. Hypermethylation of the CpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 Locus, occurs in a large percentage of human breast cancers. *Cancer Res.* 61, 3105–3109.
- Dawson, S., Makretsov, N., Blows, F.M., Driver, K.E., Provenzano, E., Quesne, J. Le, Baglietto, L., 2010. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. *Br. J. Cancer* 103, 668–675.
- Dent, R., Trudeau, M., Pritchard, K.I., Hanna, W.M., Kahn, H.K., Sawka, C.A., Lickley, L.A., Rawlinson, E., Sun, P., Narod, S.A., 2007. Triple-negative breast cancer: Clinical features and patterns of recurrence. *Clin. Cancer Res.* 13, 4429–4434.
- Devi, C.R.B., Tang, T.S., Corbex, M., 2012. Incidence and risk factors for breast cancer subtypes in three distinct South-East Asian ethnic groups: Chinese,

- Malay and natives of Sarawak, Malaysia. *Int. J. Cancer* 131, 2869–2877.
- Ehinger, A., Malmström, P., Bendahl, P.-O., Elston, C.W., Falck, A.-K., Forsare, C., Grabau, D., Rydén, L., Stål, O., Fernö, M., 2017. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013. *Acta Oncol. (Madr)*. 56, 68–74.
- El-Hawary, A.K., Abbas, A.S., Elsayed, A.A., Zalata, K.R., 2012. Molecular subtypes of breast carcinoma in Egyptian women: Clinicopathological features. *Pathol. Res. Pract.* 208, 382–386.
- Elesawy, B.H., Abd, A., Shawky, A.E., Arafa, M., 2014. Annals of Diagnostic Pathology Immunohistochemistry-based subtyping of breast carcinoma in Egyptian women ☆ A clinicopathologic study on 125 patients. *Ann. Diagn. Pathol.* 18, 21–26.
- Elston, C.W., Ellis, I.O., 1991. pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. *Histopathology* 19, 403–410.
- Engström, M.J., Opdahl, S., Hagen, A.I., Romundstad, P.R., Akslen, L.A., Haugen, O.A., Vatten, L.J., Bofin, A.M., 2013. Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. *Breast Cancer Res. Treat.* 1–11.
- Errahhali, M.E., Errahhali, M.E., Ouarzane, M., Harroudi, T. El, Afqir, S., Bellaoui, M., 2017. First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco : series of 2260 cases. *BMC Womens. Health* 1–11.
- Faheem, M., Mahmood, H., Khurram, M., Qasim, U., Irfan, J., 2012. Estrogen receptor, progesterone receptor, and Her 2 Neu positivity and its association with tumour characteristics and menopausal status in a breast cancer cohort from northern Pakistan. *Ecancermedicalscience* 6, 1–8.
- Fehm, T., Maul, H., Gebauer, S., Scharf, A., Baier, P., Sohn, C., Jäger, W., Gebauer, G., 2005. Prediction of axillary lymph node status of breast cancer patients by tumorbiological factors of the primary tumor. *Strahlenther. Onkol.* 181, 580–6.
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., Bray, F., 2015. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *Int. J. Cancer* 136, E359–E386.
- Firdaus, V., Asri, A., Khambri, D., 2016. Hubungan Grading Histopatologi dan Infiltrasi Limfovaskular dengan Subtipe Molekuler pada Kanker Payudara Invasif di Bagian Bedah RSUP. Dr. M. Djamil Padang. *J. Kesehat.* 5, 165–172.

- Geethamala, K., Murthy, S., Vani, B., Rao, S., 2015. Histopathological Grade versus Hormone Receptor Status in Breast Carcinoma- Treasure The Past. *Int. J. Biomed. Res.* 6, 466–471.
- Goldhirsch, A., Wood, W.C., Coates, A.S., Gelber, R.D., Thu, B., 2011. Strategies for subtypes — dealing with the diversity of breast cancer : highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. *Ann. Oncol.* 22, 1736–1747.
- Gong, P., Wang, Y., Liu, G., Zhang, J., Wang, Z., 2013. New Insight into Ki67 Expression at the Invasive Front in Breast Cancer. *PLoS One* 8, 1–5.
- Guha, M., Altieri, D., Guha, M., Altieri, D.C., 2017. Survivin as a global target of intrinsic tumor suppression networks Survivin as a global target of intrinsic tumor suppression networks. *Cell Cycle* 8, 2708–2710.
- He, Z.-Y., Wu, S.-G., Yang, Q., Sun, J.-Y., Li, F.-Y., Lin, Q., Lin, H.-X., 2015. Breast Cancer Subtype is Associated With Axillary Lymph Node Metastasis: A Retrospective Cohort Study. *Medicine (Baltimore)*. 94, e2213.
- Heitz, F., Harter, P., Lueck, H.J., Fissler-Eckhoff, A., Lorenz-Salehi, F., Scheil-Bertram, S., Traut, A., Bois, A. du, 2009. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. *Eur. J. Cancer* 45, 2792–2798.
- Holm-Rasmussen, E.V., Jensen, M.B., Balslev, E., Kroman, N., Tvedskov, T.F., 2015. Reduced risk of axillary lymphatic spread in triple-negative breast cancer. *Breast Cancer Res. Treat.* 149, 229–236.
- Honrado, E., Hardisson, D., Calero, F., Mar, S., Rodr, I., Sarrio, D., Benitez, J., 2006. Prognostic Significance of Basal-Like Phenotype and Fascin Expression in Node-Negative Invasive Breast Carcinomas. *Clin Cancer Res* 12, 1533–1540.
- Howland, N.K., Driver, T.D., Sedrak, M.P., Wen, X., Dong, W., Hatch, S., Eltorky, M.A., Chao, C., 2013. Lymph node involvement in immunohistochemistry-based molecular classifications of breast cancer. *J. Surg. Res.* 185, 697–703.
- Izadi, P., Noruzinia, M., Fereidooni, F., 2012. Association of Poor Prognosis Subtypes of Breast Cancer with Estrogen Receptor Alpha Methylation in Iranian Women. *Asian Pacific J Cancer Prev* 13, 4113–4117.
- Jones, T., Neboori, H., Wu, H., Yang, Q., Haffty, B.G., Evans, S., Higgins, S., Moran, M.S., 2013. Are breast cancer subtypes prognostic for nodal involvement and associated with clinicopathologic features at presentation in early-stage breast cancer? *Ann. Surg. Oncol.* 20, 2866–2872.
- Judistira, J., 2012. Hubungan Antara Subtipe Imunohistokimia Karsinoma Payudara dengan Karakteristik Klinikopatologisnya di RSUP DR. Sardjito Yogyakarta tahun 2010-2011. *Karya Ilm. Paripurna* 1–47.

- Kadivar, M., Mafi, N., Joulaee, A., Shamshiri, A., 2012. Breast Cancer Molecular Subtypes and Associations with Clinicopathological Characteristics in Iranian Women , 2002- 2011. *Asian Pacific J Cancer Prev* 13, 1881–1886.
- Kelsey, J.L., Berkowitz, G.S., 2010. Breast Cancer Epidemiology. *Cancer Res* 48, 5615–23.
- Keyhani, E., Muhammadnejad, A., Behjati, F., Khodadadi, F., Karimlou, M., Moghaddam, F.A., 2013. Angiogenesis Markers in Breast Cancer - Potentially Useful Tools for Priority Setting of Anti-Angiogenic Agents. *Asian Pacific J Cancer Prev* 14, 7651–7656.
- Khokher, S., Qureshi, M.U., Mahmood, S., 2013. Association of Immunohistochemically Defined Molecular Subtypes with Clinical Response to Presurgical Chemotherapy in Patients with Advanced Breast Cancer. *Asian Pacific J Cancer Prev* 14, 3223–3228.
- Korsching, E., Packeisen, J., Agelopoulos, K., Eisenacher, M., Voss, R., Isola, J., van Diest, P.J., Brandt, B., Boecker, W., Buerger, H., 2002. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. *Lab Invest* 82, 1525–1533.
- Kwon, M.J., Park, S., Choi, J.Y., Oh, E., Kim, Y.J., Park, Y., Cho, E.Y., Kwon, M.J., Nam, S.J., Im, Y., 2012. Clinical significance of CD151 overexpression in subtypes of invasive breast cancer. *Br. J. Cancer* 106, 923–930.
- Lacroix, M., Leclercq, G., 2004. About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-?? gene (ESR1) in breast cancer. *Mol. Cell. Endocrinol.* 219, 1–7.
- Layeequr Rahman, R., Crawford, S.L., Siwawa, P., 2015. Management of axilla in breast cancer - The saga continues. *Breast* 24, 343–353.
- Lee, J.H., Kim, S.H., Suh, Y.J., Shim, B.Y., Kim, H.K., 2010. Predictors of axillary lymph node metastases (ALNM) in a Korean population with T1-2 breast carcinoma: triple negative breast cancer has a high incidence of ALNM irrespective of the tumor size. *Cancer Res. Treat.* 42, 30–6.
- Lips, E.H., Mulder, L., De Ronde, J.J., Mandjes, I.A.M., Koolen, B.B., Wessels, L.F.A., Rodenhuis, S., Wesseling, J., 2013. Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. *Breast Cancer Res. Treat.* 140, 63–71.
- Liu, N., Yu, Q., Liu, T., Grebeamlak, E.P., Wang, S., Zhang, R., Zhang, J., Niu, Y., 2012. P-cadherin expression and basal-like subtype in breast cancers. *Med Oncol* 29, 2606–2612.
- Livasy, C.A., Karaca, G., Nanda, R., Tretiakova, M.S., Olopade, O.I., Moore, D.T., Perou, C.M., 2006. Phenotypic evaluation of the basal-like subtype of

invasive breast carcinoma. *Mod. Pathol.* 19, 264–271.

- Loi, S., Sotiriou, C., Haibe-Kains, B., Lallemant, F., Conus, N.M., Piccart, M.J., Speed, T.P., McArthur, G. a, 2009. Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer. *BMC Med. Genomics* 2, 37.
- Maiti, B., Kundranda, M.N., Spiro, T.P., Daw, H.A., 2010. The association of metabolic syndrome with triple-negative breast cancer. *Breast Cancer Res Treat* 121, 479–483.
- Maksimovic, S., 2009. Prognostic value HER-2/neu expression in T1 to T3 breast cancer with axillary lymph node metastasis. *Breast Cancer Res.* 11, 9.
- Mehta, R.J., Jain, R.K., Leung, S., Choo, J., Nielsen, T., Huntsman, D., Nakshatri, H., Badve, S., 2012. FOXA1 is an independent prognostic marker for ER-positive breast cancer. *Breast Cancer Res. Treat.* 131, 881–890.
- Millikan, R.C., Newman, A.B., Patricia, A.C.T.A., Conway, K., Smith, A.L. V, Labbok, A.M.H., Geradts, A.J., Bensen, J.T., Jackson, A.S., Nyante, A.S., Livasy, A.C., Carey, L., Earp, A.H.S., Perou, A.C.M., 2008. Epidemiology of basal-like breast cancer. *Breast Cancer Res Treat* 109, 123–139.
- Nielsen, T.O., Hsu, F.D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., Akslen, L.A., Ragaz, J., Gown, A.M., Gilks, C.B., Van De Rijn, M., Perou, C.M., 2004. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. *Clin. Cancer Res.* 10, 5367–5374.
- Noguchi, M., Kurosumi, M., Iwata, H., Miyauchi, M., Ohta, M., Imoto, S., Motomura, K., Sato, K., Tsugawa, K., 2000. Clinical and Pathologic Factors Predicting Axillary Lymph Node Involvement in Breast Cancer. *Breast Cancer* 7, 114–123.
- Onitilo, A.A., Engel, J.M., Greenlee, R.T., Mukesh, B.N., 2009. Breast cancer subtypes based on ER/PR and Her2 expression: Comparison of clinicopathologic features and survival. *Clin. Med. Res.* 7, 4–13.
- Ono, M., Tsuda, H., Yunokawa, M., Yonemori, K., Shimizu, C., Tamura, K., Kinoshita, T., Fujiwara, Y., 2015. Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers. *Breast Cancer* 22, 141–152.
- Perou, C.M., Sùrlie, T., Eisen, M.B., Rijn, M. Van De, Jeffrey, S.S., Rees, C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A., Fluge, I., Pergamenschikov, A., Williams, C., Zhu, S.X., Lunning, P.E., Brown, P.O., Botstein, D., Grant, S., 2000. Molecular Portraits Breast Cancer. *Nature* 406, 747–752.
- Pichard, C., Plu-bureau, G., Castro, M.N., Gompel, A., 2008. Insulin resistance,

- obesity and breast cancer risk. *Maturitas* 60, 19–30.
- Polyak, K., Vogt, P.K., 2012. Progress in breast cancer research. *Proc. Natl. Acad. Sci.* 109, 2715–2717.
- Porter, P., 2008. “Westernizing” women’s risk? breast cancer in low-income countries. *N. Engl. J. Med.* 358, 213–216.
- Preat, F., Simon, P., Noel, J., 2014. Differences in breast carcinoma immunohistochemical subtypes between immigrant Arab and European women. *Diagn. Pathol.* 9, 1–5.
- Rakha, E.A., El-Sayed, M.E., Green, A.R., Lee, A.H.S., Robertson, J.F., Ellis, I.O., 2007. Prognostic markers in triple-negative breast cancer. *Cancer* 109, 25–32.
- Rakha, E. a, Reis-Filho, J.S., Baehner, F., Dabbs, D.J., Decker, T., Eusebi, V., Fox, S.B., Ichihara, S., Jacquemier, J., Lakhani, S.R., Palacios, J., Richardson, A.L., Schnitt, S.J., Schmitt, F.C., Tan, P.-H., Tse, G.M., Badve, S., Ellis, I.O., 2010. Breast cancer prognostic classification in the molecular era: the role of histological grade. *Breast Cancer Res.* 12, 207.
- Rakha, E., Reis-Filho, J.S., 2009. Basal-like breast carcinoma: from expression profiling to routine practice. *Arch. Pathol. Lab. Med.* 133, 860–868.
- Rao, C., Shetty, J., Kishan Prasad, H.L., 2013. Morphological profile and receptor status in breast carcinoma: an institutional study. *J. Cancer Res. Ther.* 9, 44–9.
- Reis-Filho, J.S., Tutt, A.N.J., 2008. Triple negative tumours: A critical review. *Histopathology* 52, 108–118.
- Reis-Filho, J.S., Weigelt, B., Fumagalli, D., Sotiriou, C., 2010. Molecular profiling: moving away from tumor philately. *Sci. Transl. Med.* 2, 47ps43.
- Rivenbark, A.G., Coleman, W.B., 2012. Field cancerization in mammary carcinogenesis - Implications for prevention and treatment of breast cancer. *Exp. Mol. Pathol.* 93, 391–398.
- Rivenbark, A.G., O’Connor, S.M., Coleman, W.B., 2013. Molecular and cellular heterogeneity in breast cancer: Challenges for personalized medicine. *Am. J. Pathol.* 183, 1113–1124.
- Santosa, P., Ghozali, A., Irianiwati, 2015. Ekspresi C-kit dan beberapa faktor klinikopatologis karsinoma payudara subtype basal-like. *Maj. Patol.* 24, 41–46.
- Sarrio, D., Mari, S., Hardisson, D., Cano, A., Moreno-bueno, G., 2008. Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype. *Cancer Res.* 68, 989–998.
- Scholzen, T., Gerdes, J., 2000. The Ki-67 protein: From the known and the

unknown. *J. Cell. Physiol.* 182, 311–322.

Schwartz, A.M., Henson, D.E., Chen, D., Rajamarthandan, S., 2014. Histologic grade remains a prognostic factor for breast cancer regardless of the number of positive lymph nodes and tumor size: A study of 161 708 cases of breast cancer from the SEER program. *Arch. Pathol. Lab. Med.* 138, 1048–1052.

Shriver, C.D., Hueman, M.T., Ellsworth, R.E., 2014. Molecular signatures of lymph node status by intrinsic subtype: gene expression analysis of primary breast tumors from patients with and without metastatic lymph nodes. *J. Exp. Clin. Cancer Res.* 33, 116.

Si, C., Jin, Y., Wang, H., Zou, Q., 2014. Association between molecular subtypes and lymph node status in invasive breast cancer. *Int J Clin Exp Pathol* 7, 6800–6806.

Siadati, S., Sharbatdaram, M., Nikbakhsh, N., Ghaemian, N., 2015. Original Article. *Iran. J. Pathol.* 10, 221–226.

Silver, D.P., Richardson, A.L., Eklund, A.C., Wang, Z.C., Szallasi, Z., Li, Q., Juul, N., Leong, C.O., Calogrias, D., Buraimoh, A., Fatima, A., Gelman, R.S., Ryan, P.D., Tung, N.M., De Nicolo, A., Ganesan, S., Miron, A., Colin, C., Sgroi, D.C., Ellisen, L.W., Winer, E.P., Garber, J.E., 2010. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. *J. Clin. Oncol.* 28, 1145–1153.

Tamaki, M., Kamio, T., Kameoka, S., Kojimahara, N., Nishikawa, T., 2013. The relevance of the intrinsic subtype to the clinicopathological features and biomarkers in Japanese breast cancer patients. *World J. Surg. Oncol.* 11, 1–13.

Tan, P.H., Bay, B.H., Yip, G., Selvarajan, S., Tan, P., Wu, J., Lee, C.H., Li, K.B., 2005. Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. *Mod Pathol* 18, 374–381.

Taneja, P., Maglic, D., Kai, F., Zhu, S., Kendig, R.D., Fry, E.A., Inoue, K., 2010. Classical and novel prognostic markers for breast cancer and their clinical significance. *Clin. Med. Insights Oncol.* 4, 15–34.

The Cancer Genome Atlas Network, 2012. Comprehensive molecular portraits of human breast tumours. *Nature* 490, 61–70.

Tran, B., Bedard, P.L., 2011. Luminal-B breast cancer and novel therapeutic targets. *Breast Cancer Res.* 13, 221.

Tsang, J.Y.S., Wong, K.H.Y., Lai, M.W.H., Lacambra, M.D., Ko, C., Chan, S.K., Lam, C.C.F., Yu, A.M.C., Tan, P., Tse, G.M., 2013. Nerve growth factor receptor (NGFR): a potential marker for specific molecular subtypes of breast cancer. *J Clin Pathol* 66, 291–296.

- Ugras, S., Stempel, M., Patil, S., Morrow, M., 2014. Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement. *Ann. Surg. Oncol.* 21, 3780–6.
- Van Calster, B., Vanden Bempt, I., Drijckoningen, M., Pochet, N., Cheng, J., Van Huffel, S., Hendrickx, W., Decock, J., Huang, H.J., Leunen, K., Amant, F., Berteloot, P., Paridaens, R., Wildiers, H., Van Limbergen, E., Weltens, C., Timmerman, D., Van Gorp, T., Smeets, A., Van Den Bogaert, W., Vergote, I., Christiaens, M.R., Neven, P., 2009. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: Triple positive tumours are more likely lymph node positive. *Breast Cancer Res. Treat.* 113, 181–187.
- Van Der Groep, P., Van Der Wall, E., Van Diest, P.J., 2011. Pathology of hereditary breast cancer. *Cell. Oncol.* 34, 71–88.
- Venkatraman, B., 2016. Identifying gaps and relative opportunities for discovering membrane proteomic biomarkers of triple-negative breast cancer as a translational priority. *Cancer Transl. Med.* 2, 137.
- Vuong, D., Simpson, P.T., Green, B., Cummings, M.C., Lakhani, S.R., 2014. Molecular classification of breast cancer. *Virchows Arch.* 465, 1–14.
- Weigelt, B., Peterse, J.L., van 't Veer, L.J., 2005. Breast cancer metastasis: markers and models. *Nat. Rev. Cancer* 5, 591–602.
- Widodo, I., Dwianingsih, E.K., Triningsih, E., Utoro, T., Soeripto, 2014. Clinicopathological features of indonesian breast cancers with different molecular subtypes. *Asian Pac. J. Cancer Prev.* 15, 6109–13.
- Widschwendter, M., Hermann, M., Amberger, A., Zeschnigk, M., Zeimet, A.G., Marth, C., 2000. Methylation and Silencing of the Retinoic Acid Receptor- α 2 Gene in Breast Cancer. *J. Natl. Cancer Inst.* 92, 1–8.
- Wolff, A.C., Hammond, M.E.H., Hicks, D.G., Dowsett, M., McShane, L.M., Allison, K.H., Allred, D.C., Bartlett, J.M.S., Bilous, M., Fitzgibbons, P., Hanna, W., Jenkins, R.B., Mangu, P.B., Paik, S., Perez, E.A., Press, M.F., Spears, P.A., Vance, G.H., Viale, G., Hayes, D.F., American Society of Clinical Oncology, College of American Pathologists, 2014. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *Arch. Pathol. Lab. Med.* 138, 241–56.
- Yan, P.S., Shi, H., Rahmatpanah, F., Hsiau, T.H.-C., Hsiau, A.H.-A., Leu, Y.-W., Liu, J.C., Huang, T.H.-M., 2003. Differential Distribution of DNA Methylation within the RASSF1A CpG Island in Breast Cancer Differential Distribution of DNA Methylation within the RASSF1A CpG Island in Breast Cancer 1. *Cancer Res.* 63, 6178–6186.

- Yang, X., Yan, L., Davidson, N.E., 2001. DNA methylation in breast cancer. *Endocr. Relat. Cancer* 8, 115–127.
- Yang, X.R., Chang-claude, J., Goode, E.L., Couch, F.J., Nevanlinna, H., Milne, R.L., Gaudet, M., Schmidt, M.K., Sinn, P., Vrieling, A., Heikkinen, T., Aittomäki, K., Heikkilä, P., Blomqvist, C., Lissowska, J., Peplonska, B., Chanock, S., Figueroa, J., Brinton, L., Hall, P., Czene, K., Humphreys, K., Darabi, H., Liu, J., Veer, L.J. Van, Leeuwen, F.E. Van, Andrulis, L., Glendon, G., Knight, J.A., Mulligan, A.M., Malley, F.P.O., Weerasooriya, N., John, E.M., Beckmann, M.W., Hartmann, A., Weihbrecht, S.B., Wachter, D.L., Jud, S.M., Loehberg, C.R., Baglietto, L., English, D.R., Giles, G.G., Mclean, C.A., Severi, G., Lambrechts, D., Vandrope, T., Weltens, C., Paridaens, R., Smeets, A., Neven, P., Wildiers, H., Balasubramanian, S.P., Reed, M.W.R., Dörk, T., Bremer, M., Meyer, A., Karstens, J.H., Ay, A., 2011. Associations of Breast Cancer Risk Factors With Tumor Subtypes : A Pooled Analysis From the Breast Cancer Association Consortium Studies. *J Natl Cancer Ins* 103, 250–263.
- Yersal, O., Barutca, S., 2014. Biological subtypes of breast cancer: Prognostic and therapeutic implications. *World J. Clin. Oncol.* 5, 412–24.
- Yoshihara, E., Smeets, A., Laenen, A., Reynders, A., Soens, J., Van Ongeval, C., Moerman, P., Paridaens, R., Wildiers, H., Neven, P., Christiaens, M.-R., 2013. Predictors of axillary lymph node metastases in early breast cancer and their applicability in clinical practice. *Breast* 22, 357–61.
- Yue, Y., Astvatsaturyan, K., Cui, X., Zhang, X., Fraa, B., Bose, S., 2016. Stratification of prognosis of triple-negative breast cancer patients using combinatorial biomarkers. *PLoS One* 11, 1–13.
- Zhang, M., Liu, H., Teng, X., Wang, H., Cui, J., Jia, S., Gu, X., Li, Z., 2012. The Differences in CXCR4 Protein Expression Are Significant for the Five Molecular Subtypes of Breast Cancer. *Ultrastruct. Pathol.* 36, 381–386.
- Zhang, M.H., Man, H.T., Zhao, X.D., Dong, N., Ma, S.L., 2014. Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review). *Biomed. reports* 2, 41–52.